Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Ligand Pharmaceuticals Incorporated

Biotech Giants' Cost Efficiency: Gilead vs. Ligand

__timestampGilead Sciences, Inc.Ligand Pharmaceuticals Incorporated
Wednesday, January 1, 201437880000009136000
Thursday, January 1, 201540060000005807000
Friday, January 1, 201642610000005571000
Sunday, January 1, 201743710000005366000
Monday, January 1, 201848530000006337000
Tuesday, January 1, 2019467500000011347000
Wednesday, January 1, 2020457200000030419000
Friday, January 1, 2021660100000062176000
Saturday, January 1, 2022565700000052827000
Sunday, January 1, 2023649800000035049000
Monday, January 1, 202428675800000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Biotech Giants: Cost Efficiency in Focus

In the competitive world of biotechnology, cost efficiency is a critical factor for success. Gilead Sciences, Inc. and Ligand Pharmaceuticals Incorporated, two prominent players in the industry, have shown contrasting trends in their cost of revenue from 2014 to 2023. Gilead Sciences, with its robust portfolio, has consistently maintained a high cost of revenue, peaking at approximately $6.6 billion in 2021. This represents a 74% increase from 2014, reflecting its expansive operations and market reach. In contrast, Ligand Pharmaceuticals, a smaller entity, has demonstrated a more volatile pattern, with its cost of revenue surging by over 580% from 2014 to 2021, reaching around $62 million. This stark difference highlights the diverse strategies and market positions of these companies. As the biotech landscape evolves, understanding these financial dynamics offers valuable insights into their operational efficiencies and strategic priorities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025